- Home
- J vs BBIO Comparison
J vs BBIO Comparison
Compare J & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | J | BBIO |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7B | 15.9B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | J | BBIO |
|---|---|---|
| Price | $139.79 | $66.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 22 |
| Target Price | ★ $162.53 | $109.10 |
| AVG Volume (30 Days) | 571.4K | ★ 2.3M |
| Earning Date | 11-19-2026 | 10-28-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | ★ $14,984,646,000.00 | $502,076,000.00 |
| Revenue This Year | $25.31 | $104.50 |
| Revenue Next Year | $4.32 | $65.29 |
| P/E Ratio | $70.54 | ★ N/A |
| Revenue Growth | 49.51 | ★ 126.26 |
| 52 Week Low | $105.68 | $52.00 |
| 52 Week High | $168.44 | $93.42 |
Technical Indicators
Market Signals| Indicator | J | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 34.40 |
| Support Level | $125.27 | $62.94 |
| Resistance Level | $138.25 | $70.37 |
| Average True Range (ATR) | 3.50 | 2.44 |
| MACD | -0.84 | 0.07 |
| Stochastic Oscillator | 29.53 | 22.45 |
Price Performance
Historical ComparisonAbout J Jacobs Solutions Inc.
Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $12 billion in revenue in fiscal 2025.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.